Figure 3
Figure 3. VEGFR-2 and CD44v6 form a complex. Signal transduction induced by HGF or VEGF-A165 in HCMECs (A) and in HAOECs (B) in the presence of a CD44v6-specific antibody (αv6), IgG control, or the human v6-specific 14mer peptide or a control peptide.15 Activation of VEGFR and Erk was measured as described in “Activation of RTKs and Erk.” Met activation has been described previously.15 (C) Immunoprecipitation with antibodies as indicated and described in “Coimmunoprecipitation” and Western blotting of the precipitates. *Treatment with the CD44v6 peptide (100 ng/mL) before immunoprecipitation with VEGFR-2 or Met antibody to demonstrate the specificity of the CD44v6 band in the Western blot. Size marker for apparent molecular weight is indicated. Vertical lines have been inserted to indicate repositioned gel lanes.

VEGFR-2 and CD44v6 form a complex. Signal transduction induced by HGF or VEGF-A165 in HCMECs (A) and in HAOECs (B) in the presence of a CD44v6-specific antibody (αv6), IgG control, or the human v6-specific 14mer peptide or a control peptide.15  Activation of VEGFR and Erk was measured as described in “Activation of RTKs and Erk.” Met activation has been described previously.15  (C) Immunoprecipitation with antibodies as indicated and described in “Coimmunoprecipitation” and Western blotting of the precipitates. *Treatment with the CD44v6 peptide (100 ng/mL) before immunoprecipitation with VEGFR-2 or Met antibody to demonstrate the specificity of the CD44v6 band in the Western blot. Size marker for apparent molecular weight is indicated. Vertical lines have been inserted to indicate repositioned gel lanes.

Close Modal

or Create an Account

Close Modal
Close Modal